This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daibata, M.
Right arrow Articles by Taguchi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daibata, M.
Right arrow Articles by Taguchi, H.

 Previous Article  |  Next Article 

Journal of Virology, May 2005, p. 5875-5879, Vol. 79, No. 9
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.9.5875-5879.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Induction of Lytic Epstein-Barr Virus (EBV) Infection by Synergistic Action of Rituximab and Dexamethasone Renders EBV-Positive Lymphoma Cells More Susceptible to Ganciclovir Cytotoxicity In Vitro and In Vivo

Masanori Daibata,1* Kentaro Bandobashi,1 Masayuki Kuroda,2 Shosuke Imai,2,3 Isao Miyoshi,1 and Hirokuni Taguchi1

Department of Hematology and Respiratory Medicine,1 Department of Molecular Microbiology and Infections, Kochi Medical School, Kochi University, Kochi 783-8505, and CREST, Japan Science and Technology Agency, Tokyo, Japan,2 CREST, Japan Science and Technology Agency, Tokyo, Japan3

Received 11 November 2004/ Accepted 21 December 2004

The purposeful induction of the lytic form of Epstein-Barr virus (EBV) infection combined with ganciclovir (GCV) treatment has been advocated as a novel strategy for EBV-positive B-cell lymphoma. We demonstrated that rituximab had a synergistic effect with dexamethasone on induction of the lytic EBV infection in CD20-positive lymphoma cells. Addition of GCV to the dexamethasone/rituximab-treated cells was more effective than dexamethasone/rituximab alone in killing EBV-positive lymphoma cells in vitro and in lymphoma-bearing nude mice but not in EBV-negative cells. These data suggest that induction of the lytic EBV infection with dexamethasone/rituximab in combination with GCV could be a potential virally targeted therapy for EBV-associated B-cell lymphoma.

* Corresponding author. Mailing address: Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi 783-8505, Japan. Phone: 81-88-880-2345. Fax: 81-88-880-2348. E-mail: daibatam{at}med.kochi-u.ac.jp.

Journal of Virology, May 2005, p. 5875-5879, Vol. 79, No. 9
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.9.5875-5879.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»